Urinary bladder cancer in Wegener's granulomatosis: Risks and relation to cyclophosphamide

Annals of the Rheumatic Diseases

Volumn 63, Issue 10, 2004, Pages 1307-1311

  Knight, A ^a   Askling, J ^b   Granath, F ^b   Sparen, P ^c   Ekbom, A ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; MESNA;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER RISK; CASE CONTROL STUDY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FOLLOW UP; HEMATURIA; HEMORRHAGIC CYSTITIS; HUMAN; MALE; PRIORITY JOURNAL; REGISTER; SMOKING; SWEDEN; WEGENER GRANULOMATOSIS;

ADULT; AGED; CASE-CONTROL STUDIES; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; URINARY BLADDER NEOPLASMS; WEGENER GRANULOMATOSIS;

EID: 4644253850     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2003.019125     Document Type: Article

References (25)

1. Talar-Williams C, Hijazi YM, Walther MM, Linehan M, Hallahan CW, Lubensky I, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener's granulomatosis. Ann Intern Med 1996;124:477-84.
2. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-98.
3. Knight A, Askling J, Ekbom A. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. Int J Cancer 2002;100:82-5.
4. Travis LB, Curtis RE, Glimelius B, Holowaty EJ, Van Leeuwen FE, Lynch CF, et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Nat Cancer Inst 1995;87:524-30.
5. Pedersen-Bjergaard J, Ersboll J, Hansen VL, Sörensen BL, Christoffersen K, Hou-Jensen K, et al. Carcinoma of the urinary bladder after the treatment with cyclophosphamide for non-Hodgkins lymphoma. N Engl J Med 1988;318:1028-32.
6. Plotz PH, Klippel JH, Decker JL, Grauman D, Woff B, Brown BC, et al. Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis. Ann Intern Med 1979;91:221-3.
7. Beauparlant P, Papp K, Haraoui B. The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum 1999;29:148-58.
8. Ansher AF, Melton JW 3rd, Sliwinski AJ. ladder malignancy in a patient receiving low dose cyclophosphamide for treatment or rheumatoid arthritis. Arthritis Rheum 1983;26:804-5.
9. Socialstyrelsen. Patientregistret. Quality and content. Stockholm: Socialstyrelsen, 1987-96.
10. Mattsson B, Wallgren A. Completeness of the Swedish Cancer Register. Non-notified cancer cases recorded on death certificates in 1978. Acta Radiol Oncol 1984;23:305-13.
11. Breslow NE, Day NE. Statistical methods in cancer research. Volume II. The design and analysis of cohort studies. IARC Sci Publ 1987;82:1-406.
12. Cary. Changes and enhancements through release 6.12. SAS Institute Inc. SAS/STAT Software 1997:247-348.
13. Fauci A, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutical experience with 85 patients for 21 years. Ann Intern Med 1983;98:76-85.
14. Centre for Epidemiology NBoHaW. Cancer Incidence in Sweden, 2001. http://www.sos.se/epc (accessed 11 July 2004).
15. Jayne D, Rasmussen N, Andrassy K, Bacon P, Cohen Tervaert JW, Dadoniene J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44.
16. Cox P. Cyclophosphamide cystitis-identification of acrolein as the causative agent. Biochem Pnarmacol 1979;28:2045-9.
17. Brandau S, Böhle A. Bladder cancer. Eur Urol 2001;39:491-7.
18. Fernandes ET, Manivel JC, Reddy PK, Ercole CJ. Cyclophosphamide associated bladder cancer - a highly aggressive disease: Analysis of 12 cases. J Urol 1996;156:1931-3.
19. Khan MA, Travis LB, Lynch CF, Soini Y, Hruszkewycz AM, Delgado RM, et al. p53 mutations in cyclophosphamide-associated bladder cancer. Cancer Epidemiol Biomarkers Prev 1998,7:397-403.
20. Tatsis E, Reinhold-Keller E, Steindorf K, Feller AC, Gross WL. Wegener's granulomatosis associated with renal cell carcinoma. Arthritis Rheum 1999;42:751-6.
21. Mellemkjaer L, Andersen V, Linet MS, Gridley G, Hoover R, Olsen JH. Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:761-8.
22. Baker GL, Kahl LE, Zee BC, Stolzer BL, Agarwal AK, Medsger TA. Malignancy following treatment of rheumatoid arthritis with Cyclophosphamide. Am J Med 1987;83:1-9.
23. Radis CD, Kahl LE, Baker GL, Wasko MCM, Cash JM, Gallatin A, et al. Effects of cyclophosphamnide on the delelopment of malignancy and on long term survival of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:1120-7.
24. De Ridder D, van Poppel H, Demonty L, D'Hooghe B, Gonsette R, Carton H, et al. Bladder cancer in patients with multiple sclerosis treated with Cyclophosphamide. J Urol 1998;159:1881-4.
25. Stillwell TJ, Benson RC Jr, DeRemee RA, McDonald TJ, Weiland LH. Cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis. Arthritis Rheum 1988;31:465-70.